Dear Editor,
In the new European guideline on the management of non-gonococcal urethritis (NGU), it is recommended to confirm urethritis by urethral smear microscopy before treatment and to test male patients with urethritis for Mycoplasma genitalium when possible. 1 The new preferred syndromic regimen for NGU is doxycycline 100 mg twice daily for seven days. Second line includes azithromycin 500 mg single dose, then 250 mg for four days. Azithromycin 1 g is no longer recommended as first-line therapy because of the increased risk of inducing macrolide resistance of M. genitalium.
However, in many settings, microscopy is not available to confirm urethritis and to exclude infection with Neisseria gonorrhoeae with a point-of-care diagnostic tool (e.g. Gram, methylene blue or gentian violet stain microscopy). As an example, in Belgium, only one centre performs microscopic examination at the sexually transmitted infection consultation in selected cases. A syndromic regimen is given at the first consultation (after specimen collection for laboratory testing) when symptoms are severe, purulent urethral discharge at exam is present or if there is a doubt about the compliance of the patient to return at the consultation.
When a syndromic treatment is given and an infection with N. gonorrhoeae cannot be excluded, what is the best choice of treatment? This point is not clarified by this new European guideline on the management of NGU and will probably raise questions in many settings.
Moreover, there is no FDA-approved test for M. genitalium, which is only routinely available in a few settings. The prevalence of M. genitalium in patients with NGU is estimated between 6 and 50%, and doxycycline is ineffective in more than 50%. Studies have shown an increase in macrolide resistance of M. genitalium and a decrease of microbiologic cure even after extended courses of azithromycin (five days) and after a single 2 g dose. 2 If point-of-care diagnostic tools are not available, US and European guidelines recommend to give drug regimens effective against both N. gonorrhoeae and Chlamydia trachomatis. 3, 4 US and European guidelines recommend a dual therapy against gonorrhoea with ceftriaxone and azithromycin (1 g or 2 g according to the US or European guidelines) to avoid development of resistance. The use of azithromycin as the second antimicrobial is preferred to doxycycline because of the substantially higher prevalence of gonococcal resistance to tetracycline than to azithromycin and for convenience and compliance advantages of single-dose therapy.
Ideally, microscopy should be available in more settings, and the clinician should have time to perform a test to exclude N. gonorrhoeae. In practice, we are far from this situation in a lot of settings.
What is then the best choice of treatment when syndromic treatment is given and infection with N. gonorrhoeae is not excluded? Ceftriaxone and azithromycin 2 g to avoid development of resistance in gonorrhoeae or ceftriaxone and doxycycline to avoid increase macrolide resistance in case of M. genitalium? This point should be discussed by experts and recommendations should be generated.
